Inovio Pharmaceuticals (INO) Research & Development (2010 - 2026)
Inovio Pharmaceuticals (INO) posted Research & Development of $14.1 million for Q1 2026, up 37.12% sequentially from $10.3 million in Q4 2025, and down 12.56% YoY from $16.1 million in Q1 2025.
Inovio Pharmaceuticals (INO) Research & Development (2010 - 2026) Analysis & Trends
Inovio Pharmaceuticals has reported Research & Development for 17 years, with the latest figure at $14.1 million in Q1 2026.
- Quarterly Research & Development fell 12.56% year-over-year to $14.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $52.2 million (down 26.29% YoY) and the FY2025 annual result came in at $54.2 million, down 28.32% from the prior year.
- Research & Development advanced to $14.1 million in Q1 2026 per INO's latest filing, from $10.3 million in the prior quarter.
- Over five years, Research & Development peaked at $56.5 million in Q2 2022 and troughed at $10.3 million in Q4 2025.
- A 5-year average of $24.6 million and a median of $18.7 million in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2023: Research & Development soared 43.37% in 2022, then slumped 59.04% in 2023.
- Over 5 years, Research & Development stood at $42.1 million in 2022, then plunged by 59.04% to $17.3 million in 2023, then dropped by 25.31% to $12.9 million in 2024, then fell by 20.37% to $10.3 million in 2025, then soared by 37.12% to $14.1 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $14.1 million, $10.3 million, and $13.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Inovio Pharmaceuticals | 97.94 Mn | 97.94 Mn | - | 10.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.83 Mn |
| Mar 31, 2026 | 14.07 Mn |
| Dec 31, 2025 | 10.26 Mn |
| Sep 30, 2025 | 13.33 Mn |
| Jun 30, 2025 | 14.52 Mn |
| Mar 31, 2025 | 16.09 Mn |
| Dec 31, 2024 | 12.89 Mn |
| Sep 30, 2024 | 18.73 Mn |
| Jun 30, 2024 | 23.09 Mn |
| Mar 31, 2024 | 20.91 Mn |
| Dec 31, 2023 | 17.25 Mn |
| Sep 30, 2023 | 15.50 Mn |
| Jun 30, 2023 | 23.74 Mn |
| Mar 31, 2023 | 30.18 Mn |
| Dec 31, 2022 | 42.12 Mn |
| Sep 30, 2022 | 33.09 Mn |
| Jun 30, 2022 | 56.46 Mn |
| Mar 31, 2022 | 55.98 Mn |
| Dec 31, 2021 | 92.30 Mn |
| Sep 30, 2021 | 47.09 Mn |